Skip to main content

Advertisement

SpringerLink
Log in

Prevalence and natural history of Graves’ orbitopathy in the XXI century

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Graves’ orbitopathy (GO) is an autoimmune disorder and the main extrathyroidal expression of Graves’ disease. There is a spectrum of ocular involvement in Graves’ disease, from complete absence of symptoms and signs to sight-threatening conditions. The prevalence of GO varies in different published series of Graves’ patients, due to confounding factors (new diagnosis vs long-lasting disease, way of defining and assessing ocular involvement, treatment of hyperthyroidism with potentially GO-modifying treatments, such as radioiodine). Recent studies, however, suggest that most Graves’ patients have mild or no GO at presentation, while moderate-to-severe GO is rare, and sight-threatening GO (mostly due to dysthyroid optic neuropathy) is exceptional in non-tertiary referral centers. The natural course of GO is incompletely defined, particularly in patients with moderate-to-severe GO, because these patients require prompt and disease-modifying therapies for orbital disease. In patients with mild GO at presentation, progression to severe forms is rare, while partial or complete remission is frequent. Progression of pre-existing GO or de novo occurrence of GO is more likely in smokers. There seems to be a trend towards a decline in progression of GO, possibly due to a better control of risk factors (cigarette smoking, thyroid dysfunction, etc.) and a closer interaction between endocrinologists and ophthalmologists allowing an improved integrated management of thyroid and orbital disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brent GA. Graves’ disease. N Engl J Med 2008, 358: 2594–605.

    Article  Google Scholar 

  2. Bartalena L, Tanda ML. Clinical practice — Graves’ ophthalmopathy. N Engl J Med 2009, 360: 994–1001.

    Article  Google Scholar 

  3. Bahn RS. Mechanisms of disease — Graves’ ophthalmopathy. N Engl J Med 2010, 362: 726–38.

    Article  PubMed Central  Google Scholar 

  4. Smith TJ. Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Invest 2010, 33: 414–21.

    Article  Google Scholar 

  5. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002, 12: 855–60.

    Article  Google Scholar 

  6. Bartalena L, Marcocci C, Pinchera A. Graves’ disease: a preventable disease? Eur J Endocrinol 2002, 146: 457–61.

    Article  Google Scholar 

  7. Tanda ML, Lai A, Bartalena L. Relation between Graves’ orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions. Clin Endocrinol (Oxf) 2008, 69: 845–7.

    Article  Google Scholar 

  8. Bartalena L. Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012, 26: 371–9.

    Article  Google Scholar 

  9. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008, 158: 273–85.

    Article  Google Scholar 

  10. Menconi F, Marinò M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007, 92: 1653–8.

    Article  Google Scholar 

  11. Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011, 96: 592–9.

    Article  Google Scholar 

  12. Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid 2011, 21: 279–83.

    Article  Google Scholar 

  13. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid 2011, 21: 951–6.

    Article  Google Scholar 

  14. Leo M, Marcocci C, Pinchera A, et al. Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 2012, 97: E44–8.

    Article  Google Scholar 

  15. De Bellis A, Conzo G, Cennamo G, et al. Time course of Graves’ ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 2012, 41: 320–6.

    Article  Google Scholar 

  16. Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 2012, 97: 4454–63.

    Article  Google Scholar 

  17. Baldeschi L. Rehabilitative surgery: In: Wiersinga WM, Kahaly GJ (eds.), Graves’ orbitopathy — a multidisciplinary approach, questions and answers, 2nd ed., Basel: Karger. 2010, 167–70.

    Google Scholar 

  18. Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves’ ophthalmopathy. 2012. Best Pract Res Clin Endocrinol Metab 2012, 26: 339–58.

    Article  Google Scholar 

  19. Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012, 26: 273–9.

    Article  Google Scholar 

  20. Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993, 14: 747–93.

    Google Scholar 

  21. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168–99.

    Google Scholar 

  22. Werner SC, Coelho B, Quimby EH. Ten year results of I-131 therapy in hyperthyroidism. Bull NY Acad Med 1957, 33: 783–806.

    Google Scholar 

  23. Hales IB, Rundle FF. Ocular changes in Graves’ disease. A long-term follow-up study. Q J Med 1960, 29: 113–26.

    Google Scholar 

  24. Hamilton RD, Mayberry VE, McConahey WM, Hanson KC. Ophthalmopathy of Graves’ disease: a comparison between patients treated surgically and patients treated with radioiodine. Mayo Clin Proc 1967, 42: 812–8.

    Google Scholar 

  25. Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G, Utiger R. Studies on the pathogenesis of the ophthalmopathy of Graves’ disease. J Clin Endocrinol Metab 1967, 27: 582–93.

    Article  Google Scholar 

  26. Jones DIR, Munro DS, Wilson GM. Observations on the course of exophthalmos after 131I therapy. Proc R Soc Med 1969, 62: 15–8.

    PubMed Central  Google Scholar 

  27. Sridama V, DeGroot LJ. Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med 1989, 80: 70–3.

    Article  Google Scholar 

  28. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992, 326: 1733–8.

    Article  Google Scholar 

  29. Tellez M, Cooper J, Edmonds C. Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992, 36: 291–4.

    Article  Google Scholar 

  30. Lim SL, Lim AK, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves’ disease. Thyroid 2008, 18: 1297–301.

    Article  Google Scholar 

  31. Noth D, Gebauer M, Müller B, Bürgi U, Diem P. Graves’ ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly 2001, 131: 603–9.

    Google Scholar 

  32. Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 2011, 165: 899–905.

    Article  Google Scholar 

  33. Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013, 98: 1443–9.

    Article  Google Scholar 

  34. Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387–9.

  35. Dolman PJ. Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 2012, 26: 229–48.

    Article  Google Scholar 

  36. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998, 49: 21–8.

    Article  Google Scholar 

  37. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995, 42: 45–50.

    Article  Google Scholar 

  38. Bartley GB. The epidemiological characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994, 92: 477–588.

    PubMed Central  Google Scholar 

  39. Laurberg P, Berman DC, Bulow Pedersen I, Andersen S, Carlé A. Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 2012, 97: 2325–32.

    Article  PubMed Central  Google Scholar 

  40. Bartalena L, Marcocci C, Lai A, Tanda ML. Graves’ hyperthyroidism of recent onset and Graves’ orbitopathy: to ablate or not to ablate the thyroid? J Endocrinol Invest 2008, 31: 578–81.

    Article  Google Scholar 

  41. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) 1989, 120: 473–8.

    Google Scholar 

  42. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A. Relationship between Graves’ ophthalmopathy and type of treatment of Graves’ hyperthyroidism. Thyroid 1992, 2: 171–8.

    Article  Google Scholar 

  43. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 1989, 121(Suppl 2): 185–9.

    Google Scholar 

  44. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 1990, 150: 1098–101.

    Article  Google Scholar 

  45. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998, 338: 73–8.

    Article  Google Scholar 

  46. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008, 69: 943–50.

    Article  Google Scholar 

  47. Traisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009, 94: 3700–7.

    Article  Google Scholar 

  48. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989, 321: 1349–52.

    Article  Google Scholar 

  49. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010, 95: 1333–7.

    Article  Google Scholar 

  50. Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves’ ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999, 51: 503–8.

    Article  Google Scholar 

  51. Hamilton HE, Schultz RO, De Gowin EL. The endocrine eye lesion in hyperthyroidism. Its incidence and course in 165 patients treated for thyrotoxicosis with iodine-131. Arch Intern Med 1960, 105: 675–85.

    Article  Google Scholar 

  52. Aranow H Jr, Day RM. Management of thyrotoxicosis in patients with ophthalmopathy: antithyroid regimen determined primarily by ocular manifestations. J Clin Endocrinol Metab 1965, 25: 1–10.

    Article  Google Scholar 

  53. Solem JH, Segaard E, Ytteborg J. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med Scand 1979, 205: 111–4.

    Article  Google Scholar 

  54. Streeten DH, Anderson GH JR, Reed GF, Woo P. Prevalence, natural history, and surgical treatment of exophthalmos. Clin Endocrinol (Oxf) 1987, 27: 125–33.

    Article  Google Scholar 

  55. Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA 1993, 269: 479–82.

    Article  Google Scholar 

  56. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996, 45: 477–81.

    Article  Google Scholar 

  57. Wiersinga WM. Combined thyroid eye clinic: the importance of a multidisciplinary health care in patients with Graves’ orbitopathy. Pediatr Endocr Rev 2010, 7(Suppl 2): 250–3.

    Google Scholar 

  58. Karlsson FA, Dahlberg PA, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol (Copenh) 1989, 121(Suppl 2): 132–41.

    Google Scholar 

  59. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011, 364: 1920–31.

    Article  Google Scholar 

  60. Perros P, Wiersinga WM. The Amsterdam declaration on Graves’ orbitopathy. Thyroid 2010, 20: 245–6.

    Article  Google Scholar 

  61. Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002, 146: 751–7.

    Article  Google Scholar 

  62. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab 2013, 98: 145–52.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical & Experimental Medicine, University of Insubria, Endocrine Unit, Ospedale di Circolo, Viale Borri, 57, 21100, Varese, Italy

    E. Piantanida, M. L. Tanda, A. Lai, L. Sassi & L. Bartalena MD

Authors
  1. E. Piantanida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Sassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Bartalena MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bartalena MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piantanida, E., Tanda, M.L., Lai, A. et al. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36, 444–449 (2013). https://doi.org/10.3275/8937

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8937

Key-words

Search

Navigation